SavedAdd your journal

Journals / İzmir Tepecik Eğitim Hastanesi Dergisi / 2020 / Cilt: 30 - Sayı: 0

COVID-19: Treatment In Pediatric Patients

COVID-19: Çocuk Hastalarda Tedavi

Aslıhan ŞAHİN
Ahu KARA AKSAY
Pages
135–141
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, treatment recommendations for pediatric patients are summarized.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:SARS-CoV-2 disease has become an important health problem for all countries because it is highly contagious.
📊
Key Findings & Data:The antiviral effects of remdesivir, favipiravir, chloroquine, hydroxychloroquine, ritonavir/lopinavir, interferon-α, and antiviral effects of other potential drugs are promising for COVID-19 treatment.
💡
Conclusion & Impact:In this review, treatment recommendations for pediatric patients are summarized.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

SARS-CoV-2 disease has become an important health problem for all countries because it is highly contagious. There is no proven and approved treatment to treat the disease. Management of the disease is mainly based on supportive therapy, treatment of symptoms, and prevention of respiratory failure. The antiviral effects of remdesivir, favipiravir, chloroquine, hydroxychloroquine, ritonavir/lopinavir, interferon-α, and antiviral effects of other potential drugs are promising for COVID-19 treatment. The roles of teicoplanin, monoclonal antibody and immunomodulators in treatment are being investigated. Considering that COVID-19 leads a milder and a more moderate course in pediatric patients than adult patients, treatment options are more limited. However, clinical studies are continuing at full speed in order to develop effective vaccine and treatment methods against the virus. In this review, treatment recommendations for pediatric patients are summarized.

Özet

SARS-CoV-2 enfeksiyonu, oldukça bulaşıcı olması nedeniyle tüm ülkeler için önemli bir sağlık sorunu hâline gelmiştir. Hastalığı tedavi etmek için henüz kanıtlanmış ve onaylanmış bir tedavi yoktur. Hastalığın yönetimi esas olarak destekleyici tedaviye, semptomların tedavisine ve solunum yetmezliğinin önlenmesine dayanmaktadır. COVID-19 tedavisi için remdesivir, favipiravir, klorokin, hidroksiklorokin, ritonavir/lopinavir, inteferon-α ve diğer potansiyel ilaçların antiviral etkileri umut vermektedir. Teikoplaninin, monoklonal antikorların ve immünmodülatörlerin tedavideki rolleri araştırılmaktadır. Çocuk yaş grubunda COVID-19’un erişkin hastalara göre daha hafif ve ılımlı geçtiği gözönüne alınırsa tedavi seçenekleri daha kısıtlıdır. Fakat virüse karşı etkin aşı ve tedavi yöntemlerinin geliştirilebilmesi için klinik çalışmalar son hızıyla devam etmektedir. Bu derlemede çocuk hastalardaki tedavi önerileri özetlenmektedir.

🔖

Cite This Article

ŞAHİN, A., AKSAY, A. K. (2020). COVID-19: Treatment In Pediatric Patients. İzmir Tepecik Eğitim Hastanesi Dergisi, Cilt: 30 - Sayı: 0, 135–141. https://ajindex.com/articles/168544

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Tu YF, Chien CS, Yarmishyn AA, et al. A review of Sars-CoV-2 and the ongoing clinical trials. Int J Mol Sci. 2020
  2. 21(7). [CrossRef] 2. Pang J, Wang MX, Ang IYH, et al. Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019- nCoV): A Systematic Review. J Clin Med. 2020
  3. 9(3):623. [CrossRef] 3. Lu X, Zhang L, Du H, et al. SARS-CoV-2 Infection in Children. N Engl J Med. 2020
  4. 382(17):1663-5. [CrossRef] 4. Tezer H, Bedi̇r Demi̇rdağ T. Novel Coronavirus disease (COVID-19) in children. TURKISH J Med Sci. 2020. [CrossRef] 5. Jean SS, Lee PI, Hsueh PR. Treatment options for COVID-19: The reality and challenges. J Microbiol Immunol Infect. 2020
  5. . [CrossRef] 6. Centers for Disease Control and Prevention. Infection Control: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 2020
  6. https://www.cdc.gov/ coronavirus/2019-ncov/hcp/infection-controlrecommendations.html. Accessed May 1, 2020. 7. WHO. Home care for patients with COVID-19 presenting with mild symptoms and management of their contacts: interim guidance, 17 March 2020. World Heal Organ. 2020
  7. (March). https://www.who.int/publications-detail/ home-care-for-patients-with-suspected-novel-coronavirus- (ncov)-infection-presenting-with-mild-symptoms-andmanagement-of-contacts. Accessed May 1, 2020. 8. Shen K, Yang Y, Wang T, et al. Diagnosis, treatment, and prevention of 2019 novel coronavirus infection in children: experts’ consensus statement. World J Pediatr. February 2020:1-9. [CrossRef] 9. Shen K-L, Yang Y-H, Jiang R-M, et al. Updated diagnosis, treatment and prevention of COVID-19 in children: experts’ consensus statement (condensed version of the second edition). World J Pediatr. April 2020:1-8. [CrossRef] 10. Day M. Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists. BMJ. 2020
  8. m1086. [CrossRef] 11. FDA: No Scientific Evidence That NSAID Use Worsens COVID19 Symptoms | Drug Topics. https://www.drugtopics.com/ latest/fda-no-scientific-evidence-nsaid-use-worsens-covid19-symptoms. Accessed May 2, 2020. 12. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020
  9. 8(4):420-422. [CrossRef] 13. Chen ZM, Fu JF, Shu Q, et al. Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus. World J Pediatr. 2020. [CrossRef] 14. Jean S-S, Chang Y-C, Lin W-C, Lee W-S, Hsueh P-R, Hsu C-W. Epidemiology, T